A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Progression-free survival (PFS), defined as the time from randomization to disease progression as assessed by the investigator per RECIST v1.1
up to approximately 26 months
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
GO27912
NCT01493843
January 2012
March 2016
Name | Location |
---|---|
New Britain, Connecticut 06052 | |
Albany, Georgia 31701 | |
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
McLean, Virginia 22101 | |
Little Rock, Arkansas 72205-7199 | |
Omaha, Nebraska 68114 | |
Albuquerque, New Mexico 87131-5636 | |
Baltimore, Maryland 21287 | |
Boston, Massachusetts | |
Charlotte, North Carolina | |
Indianapolis, Indiana | |
Las Vegas, Nevada 89109 |